Chimeric Therapeutics Limited (CHMMF)

Market Cap	6.09M -25.2%
Revenue (ttm)	6.50M +377.6%
Net Income	-12.53M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,000
Average Volume	20,438
Open	0.0010
Previous Close	0.0300
Day's Range	0.0010 - 0.0010
52-Week Range	0.0010 - 0.0350
Beta	1.40
RSI	n/a
Earnings Date	May 28, 2026

About Chimeric Therapeutics

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHMMF

Financial Performance

In fiscal year 2025, Chimeric Therapeutics's revenue was 12.68 million, an increase of 70.09% compared to the previous year's 7.46 million. Losses were -10.43 million, -16.76% less than in 2024.

Financial numbers in AUD